Factors influencing haemopoietic recovery following chemotherapy-mobilised autologous peripheral blood progenitor cell transplantation for haematological malignancies: A retrospective analysis of a 10-year single institution experience

Bone Marrow Transplantation

Volumn 22, Issue 8, 1998, Pages 763-770

  Lowenthal, R M ^a,b   Faberes C ^a   Marit, G ^a   Boiron, J M ^a   Cony Makhoul, P ^a   Pigneux, A ^a   Agape, P ^a   Vezon, G ^a   Bouzgarou, R ^a   Dazey, B ^a   Fizet, D ^a   Bernard, P ^a   Lacombe, F ^a   Reiffers, J ^a  

^a CNRS Bordeaux Segalen University   (France)

^b ROYAL HOBART HOSPITAL   (Australia)

Author keywords

Autologous; G CSF; Multiple myeloma; Stem cell transplantation

Indexed keywords

AMPHOTERICIN; ANTIBIOTIC AGENT; BUSULFAN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; GROWTH FACTOR;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; AUTOTRANSPLANTATION; CHILD; COLONY FORMING UNIT GM; FEMALE; GRANULOCYTE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SOLID TUMOR; STEM CELL; THROMBOCYTE; WHOLE BODY RADIATION;

EID: 18244414014     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701435     Document Type: Article

References (47)

1. Juttner CA, To LB, Haylock DN et al. Circulating autologous stem cells collected in very early remission from acute non-lymphoblastic leukaemia produce prompt but incomplete haemopoietic reconstitution after high dose melphalan or supralethal chemoradiotherapy. Br J Haematol 1985; 61: 739-745.
2. Reiffers J, Bernard PH, David B et al. Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukemia. Exp Hematol 1986; 14: 312-315.
3. Schmitz N, Dreger P, Zander AR et al. Results of a randomised, controlled, multicentre study of recornbinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1995; 15: 261-266.
4. Powles R, Mehta J, Singhal S et al. Autologous bone marrow or peripheral blood stem cell transplantation followed by maintenance chemotherapy for adult acute lymphoblastic leukemia in first remission: 50 cases from a single center. Bone Marrow Transplant 1995; 16: 241-247.
5. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831.
6. Nemunaitis J, Rabinowe SN, Singer JW et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation. New Engl J Med 1991; 324: 1773-1778,
7. Chan WC, Wu GQ, Greiner TC et al. Detection of tumor con- tamination of peripheral stem cells in patients with lymphoma using cell culture and polymerase chain reaction technology. J Hematother 1994; 3: 175-184.
8. Brugger W, Bross KJ, Glatt M et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636-640.
9. Shpall EJ, Jones RB. Release of tumor cells from bone marrow. Blood 1994; 83: 623-625.
10. Chao NJ, Schriber JR, Grimes K et al. Granulocyte colonystimulating factor 'mobilized' peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031-2035.
11. Peters WP, Rosner G. Ross M et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709-1719.
12. Smith TJ, Hillner BE, Schmitz N el al. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkn's lymphoma, J Clin Oncol 1997; 15: 5-10.
13. Gratwohl A, Hermans J, Baldomero H. Hematopoietic precursor cell transplants in Europe: activity in 1994. Report from the European Group for Blood and Bone Marrow Transplantation (EBMT). Bone Marrow Transplant 1996; 17: 137-148.
14. Sheridan WP, Begley CG, To LB et al. Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies. Bone Marrow Transplant 1994; 14: 105-111.
15. Reiffers J, Faberes C, Boiron JM et al. Peripheral blood progenitor cell transplantation in 118 patients with hematological malignancies: analysis of factors affecting the rate of engraftment. J Hematother 1994; 3: 185-191.
16. Bouzgarrou R, Cristol G, Hau F et al. Cryopreservation of hematopoietic peripheral blood stem cells in Gambro freezing bags. In: Areman E, Deeg HJ, Sacher RA (eds). Bone Marrow and Stem Cell Processing FA Davis: Philadelphia, 1992, p 357.
17. Bouzgarrou R, Cristol G, Hau F et al. Infusion of peripheral blood stem cells. In: Areman E, Deeg HJ, Sacher RA (eds). Bone Marrow and Stem Cell Processing. FA Davis: Philadelphia, 1992, p 360.
18. Boiron J-M, Marit G, Fabères C et al. Collection of peripheral blood stem cells in multiple myeloma following single highdose cyclophosphamide with and without recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Bone Marrow Transplant 1993; 12: 49-55.
19. To LB, Flesch M, Maloisel F et al. Multicenter randomized double-blind placebo controlled study on efficacy of GM-CSF for collection of peripheral blood progenitor cells (PBPC) in multiple myeloma (MM) patients. Bone Marrow Transplant 1998; 21 (Suppl. 1): S200 (Abstr.),
20. Reiffers J, Stoppa AM, Attal M et al. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia 1996; 10: 1874-1882.
21. Philip T, Chauvin F, Armitage J et al. Parma International Protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 1991; 77: 1587-1592.
22. Gribben JG, Linda DC, Singer CRJ et al. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 1989; 73: 340-344.
23. Haioun C, Lepase E, Gisselbrecht C et al. Benefit of autolog- ous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. J Clin Oncol 1997; 15: 1131-1137.
24. Sutherland HJ, Eaves CJ, Lansdorp PM et al. Kinetics of committed and primitive blood progenitor mobilization after chemotherapy and growth factor treatment and their use in autotransplants. Blood 1994; 83: 3808-3814.
25. Janowska-Wieczorek A, Matsuzaki A, Sumoski W et al. Sequential mobilization and transplantation of peripheral blood stem cells. Blood 1996; 88 (Suppl. 1): (Abstr.).
26. Brandt J, Baird N, Lu L el al. Characterization of a human hematopoietic progenitor cell capable of forming blast cell containing colonies in vitro. J Clin Invest 1988; 82: 1017-1027.
27. Krause DS, Fackler MJ, Civin CI et al. CD34: structure, biology and clinical utility. Blood 1996; 87: 1-13.
28. + cell enumeration: toward a standardized flow cytometric approach. J Hematother 1996; 5: 209-210.
29. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
30. Bender JG, To LB, Williams S, Schwartzberg LS. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992; 1: 329-341.
31. + selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer. Blood 1997; 89: 1521-1528.
32. Sheridan W, Begley CG, Juttner CA et al. Effect of peripheral blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-644.
33. Nademanee A, Sniecinski I, Schmidt GM et al. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol 1994; 12: 2176-2186.
34. Zimmerman TM, Mick R, Myers S et al. Source of stem cells impacts on hematopoietic recovery after high-dose chemotherapy. Bone Marrow Transplant 1995; 15: 923-927.
35. Bensinger WI, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
36. Hartmann O, Biaise D, Michon J et al. Results of a multicentrie randomized clinical trial comparing peripheral blood stem cells (PBSC) and bone marrow (BM) graft in autologous transplantation. Blood 1995; 86 (Suppl. 1): 459a.
37. Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
38. Lowenthal RM, Sullivan SA, Parker N, Marsden KA. G-CSF-primed bone marrow cells for autologous transplantation. Lancet 1996; 347: 1125.
39. Damiani D, Fanin R, Silvestri F et al. Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients. Blood 1997; 90: 36-42.
40. Klumpp TR, Mangan KF, Goldberg SL et al. Granulocyte colony-stimulating factor accelerates neutrophil engraftment fol- lowing peripheral-blood stem cell transplantation: a prospective, randomized trial. J Clin Oncol 1995; 13: 1323-1327.
41. Link H, Boogaerts MA, Carella AM et al. A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. Blood 1992; 80: 2188-2195.
42. Gisselbrecht C, Prentice HG, Bacigalupo A et al. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet 1994; 343: 696-700.
43. Haas R, Möhle R, Frühauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3794.
44. Spitzer G, Adkins DR. Persistent problems of neutrppenia and thrombocytopenia with peripheral blood stem cell transplant tation. J Hematother 1994; 3: 193-198.
45. Elfenbein GJ, Perkins JB, Janssen WE et al. Recovery of hematopoiesis after high dose therapy and autologous peripheral blood stem cell transplantation is clearly dependent on the mobilizing regimen and the transplant regimen. Blood 1996; 88 (Suppl. 1): 407a (Abslr. 1618).
46. Fouillard L, Gorin NC, Laporte JP et al. Recombinant human granulocyte-macropnage colony-stimulating tactor plus the BEAM regimen instead of autologous bone marrow transplantation. Lancet 1989; 1: 1460.
47. Rice A, Bernard P, Foures C et al. Long-term culture of peripheral blood stem cells: the effect of the addition of an irradiated stromal layer. Exp Hematol 1989; 17: 984-988.